|
|
High Density Multiplexed Assays: Obstacles & Opportunities for Bioscience MarketsPublished by: Drug and Market Development Publishing Published: Aug. 9, 2003 - 100 Pages Table of Contents1 Executive Summary 2 Introduction To Multiplexed Assays
Enter Multiplexed Assays Scintillation Proximity Assay (SPA) - 1991 Electrochemiluminescence (ECL) Multiplexed Assay Technologies Today Luminex Illumina Quantum Dot Nanoplex 3D Molecular Sciences The Need for Multiplexing Drug Discovery and Development Clinical Diagnostics Benefits of Multiplexing 3 Applications of Multiplexed Assays Under Development
SNP Profiling Pharmacogenomics Gene Expression Profiling Proteomics Immunoassay Glycomics 4 Future Trends Impacting Multiplexed Technologies
Particle Separation & Recovery Large Scale Protein Synthesis 5 Conclusions
Key Competitive Advantages of Multiplexed Assay Technologies Over Microarrays Key Application Areas for Multiplexed Assays (High-throughput Screening, Clinical Diagnostics, etc.) Key Technological Limitations in Extending Low Density Multiplexed Assays (<50) to High Density Multiplexed Assays Impact of Technologies on Trends in Stratifying Patients 6 Company Profiles
BD Biosciences Corning Fluidigm GenoSpectra Guava Technologies Illumina Luminex Nanosphere NanoPlex Pharmaseq Quantum Dot SmartBead 3D Molecular Sciences 7 References and Resources 8 Glossary and Abbreviations AbstractD&MD’s High Density Multiplexed Assays Market Analysis Report is the only publication focused solely on the increasing commercial interest in multiplexed assay technologies. This Report identifies both the technological and strategic reasons in support of high density multiplexed assay technologies becoming a major player in disease and patient stratification over the next five years, especially in major areas such as cancer—making it essential reading for those decision-makers in the pharmaceutical, biotechnology, and clinical diagnostic industries.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||